
AstraZeneca pushes Tagrisso-chemo combo following positive progression-free survival data
AstraZeneca’s EGFR inhibitor Tagrisso (osimertinib) could be on its way to adding another lung cancer indication after the company said on Tuesday the drug plus chemo showed statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso as a monotherapy in late-stage lung cancer patients.
In the Phase III FLAURA2 trial, AstraZeneca tested out a Tagrisso-chemo combo in late-stage patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). Though no data were provided, the primary endpoint, progression-free survival, was statistically significant, according to AstraZeneca.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.